Human onchocerciasis: the essential partnership between research and disease control efforts

Insights

Onchocerciasis control has advanced significantly due to mass drug administration and vector control. Continued progress requires deeper research into parasite biology, drug development, and disease pathology for effective elimination strategies.

Area of Science:

  • Tropical medicine
  • Parasitology
  • Public health

Background:

  • Onchocerciasis, or river blindness, was once neglected but is now a model for disease management in developing nations.
  • Successes in mass vector control and drug treatment have transformed onchocerciasis control efforts.

Purpose of the Study:

  • To highlight the need for continued basic research to ensure the long-term effectiveness of onchocerciasis control programs.
  • To explore emerging research areas crucial for advancing disease control and elimination.

Main Methods:

  • Review of current onchocerciasis control strategies, focusing on ivermectin (Mectizan) and its limitations.
  • Investigation into potential new drug targets, including parasite biochemistry and the Wolbachia endosymbiont.
  • Exploration of advancements in genomics for identifying parasite strain differences and their clinical relevance.

Main Results:

  • Current control relies heavily on ivermectin, targeting only the microfilarial stage, necessitating new drug development.
  • Genomic studies reveal parasite strain differences impacting disease presentation and treatment.
  • Understanding of pathogenic mechanisms and adverse chemotherapy reactions requires further investigation.

Conclusions:

  • Continued research into parasite biochemistry, genomics, and pathology is essential for improving onchocerciasis control.
  • Development of novel anti-filarial compounds and better diagnostic tools are critical.
  • Effective monitoring and coordination with other helminth control programs are necessary for onchocerciasis elimination.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...